Nurix CSO sells shares to cover RSU taxes
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported the vesting and conversion of 10,180 Restricted Stock Units into an equal number of shares of common stock on July 30, 2026, at an exercise price of $0.00 per share.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported the vesting and conversion of 10,180 Restricted Stock Units into an equal number of shares of common stock on July 30, 2026, at an exercise price of $0.00 per share.
On the same date, Hansen sold 3,847 shares of common stock at a weighted average price of $23.3828 per share, within a range of $23.00 to $23.90. According to the disclosure, these shares were sold solely to cover tax withholding obligations under the company’s equity incentive plans through a mandated "sell to cover" transaction and were not discretionary trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Hansen Gwenn
Role
Chief Scientific Officer
Sold
3,847 shs ($90K)
Approx. gross sale proceeds
$90K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3, F4, F5 | 3,750 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F6, F5 | 2,858 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F7, F5 | 3,572 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,750 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,858 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,572 | $0.00 | $0.00 |
| Sale | Common Stock F1, F2 | 3,847 | $23.3828 | $90K |
Holdings After Transaction:
Restricted Stock Units — 70,562 contracts (Direct);
Common Stock — 121,338 shares (Direct)
Footnotes (7)
- F1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- F3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F4. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F5. RSUs do not expire; they either vest or are canceled prior to the vest date.
- F6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Key Figures
RSUs converted: 10,180 shares
Shares sold: 3,847 shares
Weighted average sale price: $23.3828 per share
+4 more
7 metrics
RSUs converted
10,180 shares
Total RSUs exercised into common stock on July 30, 2026
Shares sold
3,847 shares
Common stock sold to cover tax withholding obligations
Weighted average sale price
$23.3828 per share
Average price for the 3,847-share tax-related sale on July 30, 2026
Sale price range
$23.00–$23.90 per share
Lowest and highest prices in the mandated sell-to-cover transaction
First RSU grant vesting start
July 30, 2024
1/12 of the total award vests quarterly over three years
Second RSU grant vesting start
July 30, 2025
1/12 of the total award vests quarterly over three years
Third RSU grant vesting start
July 30, 2026
1/12 of the total award vests quarterly over three years
Key Terms
Restricted Stock Units, sell to cover, weighted average sale price, equity incentive plans
4 terms
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
weighted average sale price financial
"Represents the weighted average sale price. The lowest price at which shares were sold"
equity incentive plans financial
"mandated by the Issuer's election under its equity incentive plans to require"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Nurix Therapeutics (NRIX) report for CSO Gwenn Hansen on July 30, 2026?
On July 30, 2026, CSO Gwenn Hansen had 10,180 RSUs vest and convert into common stock and sold 3,847 shares. The sale was tied to tax withholding obligations rather than discretionary trading activity.
What are the vesting schedules for Gwenn Hansen’s Nurix Therapeutics (NRIX) RSU awards?
Three RSU grants each vest as to 1/12 of the award quarterly over three years. First increments vest on July 30, 2024, July 30, 2025, and July 30, 2026, respectively, contingent on continued service with Nurix on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
